December 17, 2021 -- SK Capital Partners, a private investment firm, has acquired a majority shareholding in Seqens, which produces active ingredients, pharmaceutical intermediates, and specialty ingredients leveraging 24 industrial sites, 10 R&D centers, and 3,200 employees on three continents.
SK Capital is investing alongside other investors that include Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium, and the company's management team.
Seqens has a product portfolio of more than 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.
No financial agreements of this acquisition are disclosed.
Copyright © 2021 scienceboard.net